Artiva Biotherapeutics, Inc.
ARTV · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $33 | $5 | $2 |
| % Growth | -99.3% | 579.2% | 146.3% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $33 | $5 | $2 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $50 | $50 | $44 | $42 |
| G&A Expenses | $17 | $14 | $21 | $13 |
| SG&A Expenses | $17 | $14 | $21 | $13 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $68 | $64 | $65 | $55 |
| Operating Income | -$67 | -$31 | -$60 | -$53 |
| % Margin | -26,805.6% | -91.6% | -1,213.3% | -2,660.9% |
| Other Income/Exp. Net | $9 | $3 | $1 | -$19 |
| Pre-Tax Income | -$58 | -$28 | -$58 | -$72 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$58 | -$28 | -$58 | -$72 |
| % Margin | -23,304% | -82.7% | -1,184.1% | -3,587.7% |
| EPS | -5.2 | -1.19 | -3.32 | -4.08 |
| % Growth | -337% | 64.2% | 18.6% | – |
| EPS Diluted | -5.2 | -1.19 | -3.32 | -4.08 |
| Weighted Avg Shares Out | 24 | 23 | 18 | 18 |
| Weighted Avg Shares Out Dil | 24 | 23 | 18 | 18 |
| Supplemental Information | – | – | – | – |
| Interest Income | $5 | $3 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $2 | $2 | $1 | $0 |
| EBITDA | -$65 | -$28 | -$59 | -$72 |
| % Margin | -25,837.1% | -84.8% | -1,189.8% | -3,575.3% |